{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:08:37Z","timestamp":1794913717879,"version":"4.9.1"},"reference-count":240,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.survophthal.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:46:49Z","timestamp":1767210409000},"page":"1090-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6754-7199","authenticated-orcid":false,"given":"Suraj","family":"Bala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia J.","family":"Abbass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra V.","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"10.1016\/j.survophthal.2025.12.007_bib4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.12.007_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/ICU.0000000000001137","article-title":"Glucagon-like peptide-1 receptor agonists and the eye","author":"Zhang","year":"2025","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib6","first-page":"1","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"issue":"S1","key":"10.1016\/j.survophthal.2025.12.007_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdi.12466","article-title":"Is GLP-1 a hormone: Whether and When?","volume":"7","author":"D\u2019Alessio","year":"2016","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.survophthal.2025.12.007_bib9","doi-asserted-by":"crossref","unstructured":"Andreasen C.R., Andersen A., Knop F.K., Vilsb\u00f8ll T. How glucagon-like peptide 1 receptor agonists work. 2021 July 1 [cited 2025 Apr 27]; doi:10.1530\/EC-21-0130.","DOI":"10.1530\/EC-21-0130"},{"key":"10.1016\/j.survophthal.2025.12.007_bib10","series-title":"StatPearls [Internet]","article-title":"Glucagon-Like Peptide-1 Receptor Agonists","author":"Collins","year":"2025"},{"key":"10.1016\/j.survophthal.2025.12.007_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-800101-1.00002-8","article-title":"Regulation of glucose homeostasis by GLP-1","volume":"121","author":"Nadkarni","year":"2014","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.survophthal.2025.12.007_bib12","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab J"},{"issue":"12","key":"10.1016\/j.survophthal.2025.12.007_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103382","article-title":"Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and Degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2005","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.toxicon.2010.12.016","article-title":"The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent","volume":"59","author":"Furman","year":"2012","journal-title":"Toxicon"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.survophthal.2025.12.007_bib20","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1523\/JNEUROSCI.3579-15.2016","article-title":"Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance","volume":"36","author":"Reiner","year":"2016","journal-title":"J Neurosci J Soc Neurosci"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","article-title":"GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function","volume":"31","author":"Timper","year":"2020","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.cdd.4401778","article-title":"ER stress and neurodegenerative diseases","volume":"13","author":"Lindholm","year":"2006","journal-title":"Cell Death Differ"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neulet.2010.09.040","article-title":"Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus","volume":"486","author":"Li","year":"2010","journal-title":"Neurosci Lett"},{"issue":"21","key":"10.1016\/j.survophthal.2025.12.007_bib26","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1007\/s00018-010-0398-3","article-title":"Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model","volume":"67","author":"Luciani","year":"2010","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br J Pharm"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib28","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s42255-023-00859-y","article-title":"Liraglutide restores impaired associative learning in individuals with obesity","volume":"5","author":"Hanssen","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","article-title":"Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages","volume":"111","author":"Tate","year":"2016","journal-title":"Basic Res Cardiol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.12.007_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/1744666X.2021.1971973","article-title":"The GLP-1 receptor in airway inflammation in asthma: a promising novel target?","volume":"17","author":"Wu","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/antiox10081175","article-title":"GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation","volume":"10","author":"Helmst\u00e4dter","year":"2021","journal-title":"Antioxid Basel Switz"},{"key":"10.1016\/j.survophthal.2025.12.007_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","article-title":"Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency","volume":"1150","author":"Xue","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.survophthal.2025.12.007_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173581","article-title":"Glucagon-like peptide-1 cleavage product GLP-1(9-36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes","volume":"887","author":"Huang","year":"2020","journal-title":"Eur J Pharm"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib36","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"10.1016\/j.survophthal.2025.12.007_bib37","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J Neurosci J Soc Neurosci"},{"key":"10.1016\/j.survophthal.2025.12.007_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104615","article-title":"Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure","volume":"152","author":"Yoon","year":"2020","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5607\/en.2017.26.4.227","article-title":"Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1\/JIP1 Expression and JNK Signaling in Stroke","volume":"26","author":"Kim","year":"2017","journal-title":"Exp Neurobiol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib40","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/jcbfm.2011.51","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia","volume":"31","author":"Teramoto","year":"2011","journal-title":"J Cereb Blood Flow Metab J Int Soc Cereb Blood Flow Metab"},{"issue":"13","key":"10.1016\/j.survophthal.2025.12.007_bib41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.survophthal.2025.12.007_bib42","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.3390\/jcm13133729","article-title":"All GLP-1 Agonists Should, Theoretically, Cure Alzheimer\u2019s Dementia but Dulaglutide Might Be More Effective Than the Others","volume":"13","author":"Fessel","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib43","first-page":"513","article-title":"Inflammation and retinal degenerative diseases","volume":"18","author":"Kaur","year":"2022","journal-title":"Neural Regen Res"},{"issue":"20","key":"10.1016\/j.survophthal.2025.12.007_bib44","doi-asserted-by":"crossref","first-page":"12428","DOI":"10.3390\/ijms232012428","article-title":"Anti-Inflammatory Effects of GLP-1R Activation in the Retina","volume":"23","author":"Puddu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/antiox9090846","article-title":"Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress","volume":"9","author":"Ramos","year":"2020","journal-title":"Antioxid Basel Switz"},{"issue":"19","key":"10.1016\/j.survophthal.2025.12.007_bib46","doi-asserted-by":"crossref","first-page":"E2655","DOI":"10.1073\/pnas.1522014113","article-title":"Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus","volume":"113","author":"Sohn","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.survophthal.2025.12.007_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107680","article-title":"Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.survophthal.2025.12.007_bib50","article-title":"Neuroprotective Role of GLP-1 Analog for Retinal Ganglion Cells via PINK1\/Parkin-Mediated Mitophagy in Diabetic Retinopathy","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharm"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15569527.2020.1844727","article-title":"Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p66Shc","volume":"40","author":"Al Sabaani","year":"2021","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pharep.2018.10.003","article-title":"Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-\u03b1 stimulated human retinal pigment epithelial cells","volume":"71","author":"Garczorz","year":"2019","journal-title":"Pharm Rep PR"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000504891","article-title":"Exendin-4 Protects Human Retinal Pigment Epithelial Cells from H2O2-Induced Oxidative Damage via Activation of NRF2 Signaling","volume":"63","author":"Cui","year":"2020","journal-title":"Ophthalmic Res"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3164\/jcbn.16-26","article-title":"Exendin-4 induces extracellular-superoxide dismutase through histone H3 acetylation in human retinal endothelial cells","volume":"59","author":"Yasuda","year":"2016","journal-title":"J Clin Biochem Nutr"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"issue":"23","key":"10.1016\/j.survophthal.2025.12.007_bib56","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.survophthal.2025.12.007_bib58","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.survophthal.2025.12.007_bib59","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.survophthal.2025.12.007_bib60","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"10193","key":"10.1016\/j.survophthal.2025.12.007_bib61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib62","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.survophthal.2025.12.007_bib63","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.12.007_bib64","unstructured":"Ozempic (semaglutide) Injection [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209637Orig1s000TOC.cfm\u3009."},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib65","first-page":"10","article-title":"Semaglutide and the risk of diabetic retinopathy-current perspective","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye Lond Engl"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib66","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib67","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis","volume":"36","author":"Yoshida","year":"2022","journal-title":"J Diabetes Complicat"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108285","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis","volume":"36","author":"Goldenberg","year":"2022","journal-title":"J Diabetes Complicat"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib70","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4093\/dmj.2022.0221","article-title":"Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists","volume":"47","author":"Lin","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.survophthal.2025.12.007_bib71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib72","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib73","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0161-6420(87)33257-9","article-title":"Effect of an insulin-induced decrease in blood glucose on the human diabetic retinal circulation","volume":"94","author":"Grunwald","year":"1987","journal-title":"Ophthalmology"},{"issue":"8295","key":"10.1016\/j.survophthal.2025.12.007_bib74","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0140-6736(82)90464-0","article-title":"Worsening of diabetic retinopathy with strict control of blood sugar","volume":"2","author":"Hooymans","year":"1982","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.survophthal.2025.12.007_bib75","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1167\/iovs.10-5264","article-title":"Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury","volume":"51","author":"Abcouwer","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib76","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjo.2003.024661","article-title":"Hypoglycaemia exacerbates ischaemic retinal injury in rats","volume":"88","author":"Casson","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib77","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/02713683.2010.521968","article-title":"The influence of glucose concentration and hypoxia on VEGF secretion by cultured retinal cells","volume":"36","author":"Kennedy","year":"2011","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib79","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-023-02753-6","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies","volume":"21","author":"Zheng","year":"2023","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.survophthal.2025.12.007_bib80","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","article-title":"Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy","volume":"8","author":"Barkmeier","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib81","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz069","article-title":"Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study","volume":"105","author":"Gaborit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib82","first-page":"1","article-title":"Glucagon-Like Peptide-1 Receptor Agonists are Not Associated with an Increased Risk of Progressing to Vision-Threatening Diabetic Retinopathy","author":"Tauqeer","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib83","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.2337\/dc18-2532","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries","volume":"42","author":"Ueda","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100547","article-title":"The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib85","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.oret.2020.08.004","article-title":"Effect of ICD-9 to ICD-10 Transition on Accuracy of Codes for Stage of Diabetic Retinopathy and Related Complications: Results from the CODER Study","volume":"5","author":"Cai","year":"2021","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100468","article-title":"Variations in Electronic Health Record-Based Definitions of Diabetic Retinopathy Cohorts: A Literature Review and Quantitative Analysis","volume":"4","author":"Chen","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.survophthal.2025.12.007_bib87","unstructured":"ClinicalTrials.gov. Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes [Internet]. clinicaltrials.gov; 2025 Feb [cited 2025 Mar 9]. Report No.: NCT03811561. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03811561\u3009."},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib88","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108196","article-title":"Diabetes Mellitus and Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib90","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/IAE.0b013e3182831248","article-title":"TEN-YEAR INCIDENCE OF AGE-RELATED MACULAR DEGENERATION ACCORDING TO DIABETIC RETINOPATHY CLASSIFICATION AMONG MEDICARE BENEFICIARIES","volume":"33","author":"Hahn","year":"2013","journal-title":"RETINA"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ophtha.2005.08.012","article-title":"Nine-Year Incidence of Age-Related Macular Degeneration in the Barbados Eye Studies","volume":"113","author":"Leske","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib92","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/09286586.2011.560746","article-title":"Statin Use and the Risk of Age Related Macular Degeneration in a Large Health Organization in Israel","volume":"18","author":"Shalev","year":"2011","journal-title":"Ophthalmic Epidemiol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib93","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.ophtha.2003.11.010","article-title":"Risk factors for incident age-related macular degeneration: Pooled findings from 3 continents","volume":"111","author":"Tomany","year":"2004","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.survophthal.2025.12.007_bib94","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.ophtha.2009.04.017","article-title":"Nine-Year Incidence and Risk Factors for Age-Related Macular Degeneration in a Defined Japanese Population: The Hisayama Study","volume":"116","author":"Yasuda","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100741","article-title":"Potential Efficacy of Metformin for Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis","volume":"5","author":"Huh","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"13","key":"10.1016\/j.survophthal.2025.12.007_bib96","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/iovs.63.13.10","article-title":"Association Between Oral Metformin Use and the Development of Age-Related Macular Degeneration in Diabetic Patients: A Systematic Review and Meta-Analysis","volume":"63","author":"Liang","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40123-021-00344-3","article-title":"Metformin, A Potential Role in Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis","volume":"10","author":"Romdhoniyyah","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193031","article-title":"Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo","volume":"13","author":"Han","year":"2018","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib99","article-title":"Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium","volume":"17","author":"Li","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.survophthal.2025.12.007_bib100","first-page":"1740943","article-title":"Metformin Protects ARPE-19 Cells from Glyoxal-Induced Oxidative Stress","volume":"2020","author":"Qu","year":"2020","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"25","key":"10.1016\/j.survophthal.2025.12.007_bib102","first-page":"00070","article-title":"Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration","volume":"S0161-6420","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.12.007_bib103","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration","author":"Shor","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib104","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.3720","article-title":"Neovascular Age-Related Macular Degeneration and GLP-1 RAs","author":"Alkabbani","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib105","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.3717","article-title":"Neovascular Age-Related Macular Degeneration and GLP-1 RAs","author":"Feldman-Billard","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib106","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.3714","article-title":"Neovascular Age-Related Macular Degeneration and GLP-1 RAs","author":"Mammo","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib107","article-title":"Neovascular Age-Related Macular Degeneration and GLP-1 RAs-Reply","author":"Shor","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib108","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.3711","article-title":"Neovascular Age-Related Macular Degeneration and GLP-1 RAs","author":"Ziemssen","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib109","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.3821","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration","author":"Ahuja","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib110","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.4090","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Use and Age-Related Macular Degeneration-Where Do We Stand?","author":"Talcott","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib111","article-title":"Impact of GLP-1 receptor agonists for type 2 diabetes mellitus on the development and progression of age-related macular degeneration","author":"McLaughlin","year":"2025","journal-title":"Retin Philos Pa"},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib112","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.oret.2023.03.011","article-title":"Coding of Geographic Atrophy and Exudative Age-related Macular Degeneration","volume":"7","author":"Park","year":"2023","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.survophthal.2025.12.007_bib113","article-title":"Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study","author":"Allan","year":"2025","journal-title":"Ophthalmol Retin [Internet]"},{"key":"10.1016\/j.survophthal.2025.12.007_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2022.848710","article-title":"Non-Arteritic Anterior Ischemic Optic Neuropathy: Challenges for the Future","volume":"2","author":"Gibbons","year":"2022","journal-title":"Front Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/S0004-27492008000100013","article-title":"Anterior ischemic optic neuropathy associated with metabolic syndrome","volume":"71","author":"Kosanovic-Jakovic","year":"2008","journal-title":"Arq Bras Oftalmol"},{"issue":"19","key":"10.1016\/j.survophthal.2025.12.007_bib116","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4103\/0366-6999.241795","article-title":"Systemic-Related Factors of Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"131","author":"Xiao","year":"2018","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib117","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/aos.17473","article-title":"Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association","author":"Amini","year":"2025","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"12","key":"10.1016\/j.survophthal.2025.12.007_bib119","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaophthalmol.2024.4518","article-title":"Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"142","author":"Xie","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.59556\/japi.72.0621","article-title":"Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?","volume":"72","author":"Singh","year":"2024","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib121","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib122","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.survophthal.2025.12.007_bib123","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib124","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.12.007_bib125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.12.007_bib126","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jamaophthalmol.2024.4527","article-title":"Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"142","author":"Maro","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib127","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib128","unstructured":"Pharmacovigilance Risk Assessment Committee. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy | European Medicines Agency (EMA) [Internet]. European Medicines Agency. 2025 [cited 2025 Nov 2]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib129","unstructured":"Should You Stop Taking GLP-1 Drugs Like Ozempic if You Experience Vision Loss? Nation\u2019s Ophthalmologists Respond to European Agency\u2019s New Recommendation [Internet]. American Academy of Ophthalmology. 2025 [cited 2025 July 15]. Available from: \u3008https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/should-you-stop-taking-glp-1-drugs-like-ozempic\u3009."},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib130","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib131","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.oret.2020.08.016","article-title":"Retinal Manifestations of Idiopathic Intracranial Hypertension","volume":"5","author":"Nichani","year":"2021","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib132","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.survophthal.2021.11.007","article-title":"Papilledema: A review of etiology, pathophysiology, diagnosis, and management","volume":"67","author":"Xie","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"404","key":"10.1016\/j.survophthal.2025.12.007_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0972","article-title":"A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus","volume":"9","author":"Botfield","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib134","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3171\/2025.1.JNS242357","article-title":"Impact of GLP-1 receptor agonists on idiopathic intracranial hypertension clinical and neurosurgical outcomes: a propensity-matched multi-institutional cohort study","volume":"143","author":"O\u2019Leary","year":"2025","journal-title":"J Neurosurg"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib135","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell","year":"2023","journal-title":"Brain J Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12987-019-0155-4","article-title":"Preclinical update on regulation of intracranial pressure in relation to idiopathic intracranial hypertension","volume":"16","author":"Eftekhari","year":"2019","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib137","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12987-025-00652-x","article-title":"Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats","volume":"22","author":"Jensen","year":"2025","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib138","first-page":"197","article-title":"Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review","volume":"37","author":"Subramaniam","year":"2017","journal-title":"J NeuroOphthalmol J North Am NeuroOphthalmol Soc"},{"issue":"10","key":"10.1016\/j.survophthal.2025.12.007_bib139","first-page":"2090","article-title":"The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study","volume":"39","author":"Kravetz","year":"2025","journal-title":"Eye Lond Engl"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s10194-023-01631-z","article-title":"Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension","volume":"24","author":"Krajnc","year":"2023","journal-title":"J Headache Pain"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib141","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamaneurol.2025.2019","article-title":"GLP-1 RAs for Idiopathic Intracranial Hypertension-Time for a Trial","volume":"82","author":"Newman","year":"2025","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib142","first-page":"254","article-title":"21st century glaucoma care","volume":"33","author":"Quigley","year":"2019","journal-title":"Eye Lond Engl"},{"issue":"25","key":"10.1016\/j.survophthal.2025.12.007_bib143","first-page":"00132","article-title":"Risk of Glaucoma in Non-Diabetic Patients using a Glucagon Like Peptide-1 Receptor Agonist","volume":"S0161-6420","author":"Vasu","year":"2025","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib144","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7150\/ijms.90273","article-title":"Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus","volume":"21","author":"Chuang","year":"2024","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101318","article-title":"Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan","volume":"48","author":"Shao","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib147","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ajo.2024.12.024","article-title":"GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis","volume":"271","author":"Amaral","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib148","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.survophthal.2025.12.007_bib149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jtos.2023.12.001","article-title":"Dry eye disease in the young: A narrative review","volume":"31","author":"Stapleton","year":"2024","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","article-title":"Dry Eye Disease: Impact on Quality of Life and Vision","volume":"1","author":"Uchino","year":"2013","journal-title":"Curr Ophthalmol Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib151","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pcd.2020.01.011","article-title":"Dry eyes in patients with diabetes mellitus","volume":"15","author":"De Freitas","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.survophthal.2025.12.007_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.980714","article-title":"Dry eye disease in patients with type II diabetes mellitus: A retrospective, population-based cohort study in Taiwan","volume":"9","author":"Pan","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.survophthal.2025.12.007_bib153","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8201053","article-title":"Dry Eye Syndrome in Patients with Diabetes Mellitus: Prevalence, Etiology, and Clinical Characteristics","volume":"2016","author":"Zhang","year":"2016","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12886-018-0781-7","article-title":"Prevalence and clinical characteristics of dry eye disease in community-based type 2 diabetic patients: the Beixinjing eye study","volume":"18","author":"Zou","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ajpath.2024.12.003","article-title":"Characterization and Role of Glucagon-Like Peptide 1 Receptor in the Lacrimal Gland: Novel Insights into Diabetic Dry Eye Pathogenesis","volume":"195","author":"Sun","year":"2025","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib156","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1080\/21655979.2022.2031418","article-title":"Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome","volume":"13","author":"Hao","year":"2022","journal-title":"Bioengineered"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib157","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32584","article-title":"Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan","volume":"5","author":"Su","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.survophthal.2025.12.007_bib158","article-title":"The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study","volume":"11","author":"Fan","year":"2023","journal-title":"Health Basel Switz"},{"issue":"11S","key":"10.1016\/j.survophthal.2025.12.007_bib159","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ophtha.2017.05.031","article-title":"Meibomian Gland Disease: The Role of Gland Dysfunction in Dry Eye Disease","volume":"124","author":"Chhadva","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.12.007_bib160","unstructured":"Exenatide [Internet]. [cited 2025 Apr 30]. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB01276\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib161","unstructured":"Drug Approval Package: Byetta [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021773_ByettaTOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib162","unstructured":"BYDUREON\u00ae (exenatide extended-release) for injectable suspension. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022200s026lbl.pdf\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib163","unstructured":"Saxenda Injection (Liraglutide [rDNA origin]) [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206321Orig1s000TOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib164","unstructured":"Liraglutide [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB06655\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib165","unstructured":"Drug Approval Package: Victoza [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022341s000TOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib166","unstructured":"Albiglutide [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB09043\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib167","unstructured":"Drug Approval Package: Tanzeum [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125431Orig1s000TOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib168","unstructured":"Drug Approval Package: Trulicity [Internet]. [cited 2025 June 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469Orig1s000TOC.cfm."},{"key":"10.1016\/j.survophthal.2025.12.007_bib169","unstructured":"Dulaglutide [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB09045\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib170","unstructured":"Lixisenatide [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB09265\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib171","unstructured":"Adlyxin (lixisenatide) Injection [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208471Orig1s000TOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib172","unstructured":"Drug Approval Package: WEGOVY [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215256Orig1s000TOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib173","unstructured":"Drug Approval Package: RYBELSUS [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213182Orig1s000TOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib174","unstructured":"Semaglutide [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB13928\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib175","unstructured":"Tirzepatide [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB15171\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib176","unstructured":"Drug Approval Package: MOUNJARO [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215866Orig1s000TOC.cfm\u3009."},{"key":"10.1016\/j.survophthal.2025.12.007_bib177","unstructured":"Drug Approval Package: ZEPBOUND [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217806Orig1s000TOC.cfm\u3009."},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib178","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/s41433-023-02908-y","article-title":"Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension","volume":"38","author":"Grech","year":"2024","journal-title":"Eye"},{"issue":"9662","key":"10.1016\/j.survophthal.2025.12.007_bib179","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"9683","key":"10.1016\/j.survophthal.2025.12.007_bib180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2025.12.007_bib181","unstructured":"Tanzeum\u00ae (albiglutide) \u2013 Drug discontinuation [Internet]. [cited 2025 June 15]. Available from: \u3008https:\/\/professionals.optumrx.com\/publications\/library\/drugwithdrawal-tanzeum-2017-0726.html\u3009."},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib182","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ceo.14445","article-title":"Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: A meta-analysis of clinical studies emphasising retinal changes as a primary outcome","volume":"53","author":"Kapoor","year":"2025","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib183","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.2337\/dc17-2285","article-title":"Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults","volume":"41","author":"Wang","year":"2018","journal-title":"Diabetes Care"},{"issue":"25","key":"10.1016\/j.survophthal.2025.12.007_bib184","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038568","article-title":"Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"103","author":"Kamrul-Hasan","year":"2024","journal-title":"Med (Baltim)"},{"issue":"17","key":"10.1016\/j.survophthal.2025.12.007_bib185","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","article-title":"Dulaglutide: First Global Approval","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib186","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib187","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib188","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgab905","article-title":"An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression","volume":"107","author":"Lingvay","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.survophthal.2025.12.007_bib189","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1111\/dom.14497","article-title":"An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg","volume":"23","author":"Pratley","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib191","doi-asserted-by":"crossref","unstructured":"Quast D., Schenker N., Menge B.A., et al. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes | Diabetes Care | American Diabetes Association [Internet]. [cited 2025 Nov 6]. Available from: \u3008https:\/\/diabetesjournals.org\/care\/article-abstract\/43\/9\/2137\/35795\/Effects-of-Lixisenatide-Versus-Liraglutide-Short?redirectedFrom=fulltext\u3009.","DOI":"10.2337\/dc20-0720"},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib192","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.12076","article-title":"Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin","volume":"15","author":"Kapitza","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.survophthal.2025.12.007_bib193","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib194","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ajpath.2020.01.011","article-title":"The Anti-Inflammatory Effects of Glucagon-Like Peptide Receptor Agonist Lixisenatide on the Retinal Nuclear and Nerve Fiber Layers in an Animal Model of Early Type 2 Diabetes","volume":"190","author":"Chung","year":"2020","journal-title":"Am J Pathol"},{"issue":"24","key":"10.1016\/j.survophthal.2025.12.007_bib195","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib196","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib197","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40261-021-01110-w","article-title":"Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials","volume":"42","author":"Wang","year":"2022","journal-title":"Clin Drug Invest"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib198","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis","volume":"143","author":"Natividade","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib199","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.2493","article-title":"Semaglutide and the Eyes-A Literature Glut, but Little Clarity","author":"Li","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib200","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/dom.15554","article-title":"Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts","volume":"26","author":"Fadini","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib201","article-title":"Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide","volume":"36","author":"Bracha","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"10300","key":"10.1016\/j.survophthal.2025.12.007_bib202","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib203","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib204","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib205","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12630-023-02521-3","article-title":"Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report","volume":"70","author":"Gulak","year":"2023","journal-title":"Can J Anaesth J Can Anesth"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib206","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can J Anaesth J Can Anesth"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib207","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.bja.2023.05.005","article-title":"Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss","volume":"131","author":"Weber","year":"2023","journal-title":"Br J Anaesth"},{"issue":"18","key":"10.1016\/j.survophthal.2025.12.007_bib208","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.3390\/jcm13185403","article-title":"Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center","volume":"13","author":"Robalino Gonzaga","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.survophthal.2025.12.007_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.survophthal.2025.12.007_bib210","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080340","article-title":"Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study","volume":"387","author":"Alkabbani","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib211","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"issue":"12","key":"10.1016\/j.survophthal.2025.12.007_bib212","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/anae.16454","article-title":"Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study","volume":"79","author":"Nersessian","year":"2024","journal-title":"Anaesthesia"},{"issue":"8","key":"10.1016\/j.survophthal.2025.12.007_bib213","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s12630-023-02549-5","article-title":"Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide","volume":"70","author":"Sherwin","year":"2023","journal-title":"Can J Anaesth J Can Anesth"},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib214","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc14-1984","article-title":"Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial","volume":"38","author":"Meier","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13741-024-00439-y","article-title":"The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis","volume":"13","author":"do Nascimento","year":"2024","journal-title":"Perioper Med Lond Engl"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib216","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/ALN.0000000000004776","article-title":"ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists","volume":"140","author":"Ushakumari","year":"2024","journal-title":"Anesthesiology"},{"key":"10.1016\/j.survophthal.2025.12.007_bib217","series-title":"In: Diretriz da Sociedade Brasileira de Diabetes [Internet]","article-title":"Rastreio e Controle da Hiperglicemia no Perioperat\u00f3rio","author":"Marino","year":"2023"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/EJA.0000000000002069","article-title":"Preoperative assessment of adults undergoing elective noncardiac surgery: Updated guidelines from the European Society of Anaesthesiology and Intensive Care","volume":"42","author":"Lamperti","year":"2025","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib219","article-title":"GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know","volume":"5","author":"Abdulrazeq","year":"2024","journal-title":"Neurosurg Pr"},{"issue":"24","key":"10.1016\/j.survophthal.2025.12.007_bib220","first-page":"00910","article-title":"Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period","volume":"S1542-3565","author":"Kindel","year":"2024","journal-title":"Clin Gastroenterol Hepatol Clin Pr J Am Gastroenterol Assoc"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib221","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib222","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/oby.23941","article-title":"Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide","volume":"32","author":"Camilleri","year":"2024","journal-title":"Obes Silver Spring Md"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib223","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cgh.2023.11.002","article-title":"AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication","volume":"22","author":"Hashash","year":"2024","journal-title":"Clin Gastroenterol Hepatol Clin Pr J Am Gastroenterol Assoc"},{"issue":"4","key":"10.1016\/j.survophthal.2025.12.007_bib224","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib225","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70019","article-title":"Efficacy of Tirzepatide Dual GIP\/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study","volume":"8","author":"Azzam","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.survophthal.2025.12.007_bib226","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.12.007_bib227","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2337\/dc17-2280","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy","volume":"41","author":"Douros","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.survophthal.2025.12.007_bib228","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","article-title":"Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database","volume":"67","author":"Eleftheriadou","year":"2024","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.survophthal.2025.12.007_bib229","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/1574886318666230420084701","article-title":"Association between Glucose-lowering Treatments and Risk of Diabetic Retinopathy in People with Type 2 Diabetes: A Nationwide Cohort Study","volume":"19","author":"Hasselstr\u00f8m Jensen","year":"2024","journal-title":"Curr Drug Saf"},{"issue":"24","key":"10.1016\/j.survophthal.2025.12.007_bib230","first-page":"00582","article-title":"Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus","volume":"S2468-6530","author":"Muayad","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib231","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2024.08.023","article-title":"Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes","volume":"132","author":"Muayad","year":"2025","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2025.12.007_bib232","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/dom.14445","article-title":"Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan","volume":"23","author":"Su","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.survophthal.2025.12.007_bib233","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jamaophthalmol.2025.0350","article-title":"Conflicting Results-Need for More Transparent and Reproducible Research","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.12.007_bib234","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamaophthalmol.2025.2822","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis","volume":"143","author":"Mohan","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.12.007_bib235","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamaophthalmol.2025.2824","article-title":"Uveitis Risk and GLP-1RA Use-Signal, Confounding, or Both?","volume":"143","author":"Toy","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.12.007_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171240","article-title":"Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship","volume":"178","author":"Hui","year":"2024","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib237","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.12.007_bib238","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3390\/jcm13061797","article-title":"Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Ma\u0142yszczak","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.survophthal.2025.12.007_bib239","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00417-023-06236-5","article-title":"Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review","volume":"262","author":"Ntentakis","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.12.007_bib240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retin Vitr"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572500236X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572500236X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:43:31Z","timestamp":1779093811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003962572500236X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":240,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S003962572500236X"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.12.007","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}